39:{"drug_id":927852,"title":"Rosuvastatin Calcium","ind":"FDA-Labeled Indications

Disorder of cardiovascular system, Primary; Prophylaxis
Familial hypercholesterolemia - homozygous
Familial type 3 hyperlipoproteinemia
Generalized atherosclerosis
Hyperlipidemia, Primary
Hypertriglyceridemia
Mixed hyperlipidemia

Non-FDA Labeled Indications

Acute coronary syndrome
Atrial fibrillation; Prophylaxis - Operation on heart
Cardiovascular event risk, Perioperative; Prophylaxis - Percutaneous coronary intervention
Metabolic syndrome
Radiographic contrast agent nephropathy; Prophylaxis
Venous thromboembolism; Prophylaxis

","adult":"$3a","ped":"Hyperlipidemia, Primary

(heterozygous familial hypercholesterolemia; aged 10 to 17 years) 5 to 20 mg ORALLY once daily; adjust dose at intervals of 4 weeks or more; MAX 20 mg daily

","side":"Common

Gastrointestinal:Abdominal pain (2.4%), Nausea (Up to 6.3%)
Musculoskeletal:Myalgia (1.9% to 12.7%)
Neurologic:Asthenia (0.9% to 4.7%), Headache (3.1% to 8.5%)

Serious

Endocrine metabolic:Diabetes mellitus (2.8%), High hemoglobin A1c level, Impaired fasting glucose
Gastrointestinal:Pancreatitis
Hepatic:Liver enzymes abnormal (1.1%), Liver failure
Musculoskeletal:Disorder of muscle (Less than 1%), Rhabdomyolysis, Rupture of tendon
Renal:Acute renal failure, Hematuria (Less than 2%), Proteinuria (1.5%)

","prgnancy":"

Rosuvastatin: X (FDA)
Rosuvastatin: D (AUS)

","intermajer":"

Amprenavir (theoretical)
Atazanavir (probable)
Ciprofibrate (probable)
Cobicistat (established)
Cyclosporine (probable)
Daptomycin (theoretical)
Darunavir (theoretical)
Dasabuvir (theoretical)
Erlotinib (theoretical)
Eslicarbazepine Acetate (probable)
Fenofibrate (theoretical)
Fenofibric Acid (theoretical)
Fosamprenavir (theoretical)
Gemfibrozil (theoretical)
Indinavir (theoretical)
Ledipasvir (theoretical)
Leflunomide (theoretical)
Lopinavir (established)
Niacin (probable)
Ombitasvir (theoretical)
Paritaprevir (theoretical)
Ritonavir (established)
Saquinavir (theoretical)
Simeprevir (established)
Teriflunomide (theoretical)

","clinical":"

Instruct patient to report signs/symptoms of myopathy or rhabdomyolysis (muscle pain, tenderness, weakness, fever).
Drug may cause nausea, abdominal pain, headache, myalgia, and asthenia.
Advise patient to immediately report signs/symptoms of myopathy including unexplained muscle pain, tenderness, or weakness especially when accompanied with fever or malaise or if symptoms persist after discontinuing treatment.
Counsel patients to report signs/symptoms of liver injury (jaundice, dark urine, upper abdominal discomfort, anorexia, fatigue).
Patient should not use any aluminum- or magnesium-containing antacids for at least 2 hours after taking this drug.
Counsel patient to avoid excessive quantities of alcohol to reduce risk of hepatotoxicity.
Advise patient that there are multiple significant drug-drug interactions for this drug. Consult healthcare professional prior to new drug use (including over-the-counter and herbal drugs).

","admin":"Oral

may be taken with or without meals at any time of the day

","interminor":"

Acenocoumarol (probable)
Amiodarone (probable)
Desogestrel (probable)
Dicumarol (probable)
Dienogest (probable)
Drospirenone (probable)
Eltrombopag (probable)
Estradiol Cypionate (probable)
Estradiol Valerate (probable)
Ethinyl Estradiol (probable)
Ethynodiol Diacetate (probable)
Etonogestrel (probable)
Fluconazole (probable)
Itraconazole (probable)
Levonorgestrel (probable)
Medroxyprogesterone Acetate (probable)
Mestranol (probable)
Norelgestromin (probable)
Norethindrone (probable)
Norgestimate (probable)
Norgestrel (probable)
Oat Bran (probable)
Pectin (probable)
Phenprocoumon (probable)
Tipranavir (established)
Warfarin (probable)

","contra":null,"clas":"Antihyperlipidemic","mode":"Rosuvastatin is a selective inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) which is the rate-limiting enzyme in cholesterol synthesis. The lipid-modifying effects result from its capacity to upregulate hepatic LDL receptors enhancing uptake and catabolism of LDL as well as its activity of inhibiting hepatic synthesis of VLDL contributing to the reduction of VLDL and LDL particles.
"}

Zerova (Rosuvastatin Calcium - NAD 40 mg) – Full Drug Info.

SCIENTIFIC NAME

INDICATIONS

CLASSIFICATION

MECHANISM OF ACTION

CLINICAL USE

ADULT DOSE

PEDIATRIC DOSE

ADMINISTRATION

CONTRAINDICATIONS

SIDE EFFECTS

PREGNANCY

MAJOR INTERACTIONS

MINOR INTERACTIONS